Physician profile
Nader G Javan
NPI 1215298823
$9,134.96
in general payments reported to CMS, 2019-2025
32 companies · $959 in 2025
The $959 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,270 · 2020: $1,073 · 2021: $1,413 · 2022: $1,568 · 2023: $1,431 · 2024: $1,421 · 2025: $959.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,791 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,790.72 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,466.67 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $1,201.39 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $1,137.56 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $713.10 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $668.31 | 2022-2025 | |
| Abbvie INC. | $512.10 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $363.19 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $353.56 | 2019-2023 | Xarelto |
| Amarin Pharma, INC. | $331.40 | 2019-2023 | |
| Astellas Pharma US INC | $303.65 | 2019-2023 | Myrbetriq |
| Amgen INC. | $277.67 | 2020-2024 | Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $276.85 | 2020-2024 | Jardiance, Tradjenta |
| Sunovion Pharmaceuticals INC. | $262.66 | 2019-2022 | |
| Abbott Laboratories | $184.39 | 2023-2025 | Freestyle Libre 3 |
| Nestle Healthcare Nutrition INC. | $166.58 | 2020-2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $129.98 | 2021-2025 | Xifaxan, Cycloset |
| Allergan, INC. | $109.42 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $104.22 | 2025 | Caplyta |
| Aimmune Therapeutics, INC. | $96.61 | 2024-2025 | Zenpep |
| Exact Sciences Corporation | $67.75 | 2023-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $53.36 | 2024-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $47.12 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $43.13 | 2019-2024 | Zoryve |
| Nevro Corp. | $43.01 | 2022 | |
| Phathom Pharmaceuticals, INC. | $41.13 | 2025 | Voquezna |
| Biohaven Pharmaceuticals, INC. | $39.39 | 2021 | |
| Inspire Medical Systems, INC. | $38.32 | 2025 | Inspire |
| Esperion Therapeutics, INC. | $33.44 | 2021-2022 | |
| Hologic Sales and Service, LLC | $22.70 | 2024 | Aptima |
| Edwards Lifesciences Corporation | $17.33 | 2020 | |
| Novartis Pharmaceuticals Corporation | $16.17 | 2023 | |
| Currax Pharmaceuticals LLC | $12.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nader Javan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.